BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services Contract Manufacturing

'Sustainable CDMO' Samsung Biologics releases 2022 ESG Report

Aims to build an eco-friendly business environment and achieve net zero GHG emissions in its operations, moving towards 100% renewable energy. Details n...

July 12, 2022 | News

WuXi XDC and AbTis Sign Memorandum of Understanding for Development and Manufacturing of Antibody Drug Conjugates

Under the partnership, AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing, ADC conjugation process developm...

July 08, 2022 | News

WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Chan...

July 07, 2022 | News

WuXi Biologics Extends Capabilities to Include Development and cGMP Manufacturing for Microbial-Derived Products

WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG14 fac...

July 05, 2022 | News

Catalent Expands Primary Packaging Capabilities at its Clinical Supply Facility in Shiga, Japan

The new blister packaging equipment is identical to that available across Catalent's clinical supply services network, offering maximum access and flexibil...

June 30, 2022 | News

WuXi STA Opens A High-Potency API Plant

The new plant adopts advanced isolation technologies with the capability to handle potent compounds with Occupational Exposure Limit (OEL) as low as 10 ng/...

June 29, 2022 | News

Merck Opens €59 Million CDMO Facility to Address Demand for Critical Cancer Therapies

Expansion doubles production of the most highly potent active pharmaceutical ingredients (HPAPIs) Merck now one of industry’s largest manufacturer...

June 24, 2022 | News

ProteoNic Announces Licensing of its 2G UNic™ Technology Platform for Production of Biologics to GenScript ProBio

Under the agreement, GenScript ProBio gains access to ProteoNic technology for the development of high-yielding cell lines for its clients. As a result, Ge...

June 15, 2022 | News

WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes

WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-...

June 06, 2022 | News

Hanmi Fine Chemical Launches 'high-tech CDMO' Business

10 billion KRW invested in Hanmi Fine Chemical facility expansion Hanmi Fine Chemical (hereinafter Hanmi FC) a subsidiary of Hanmi Pharmaceutic...

May 23, 2022 | News

Vetter Achieves a Three-Peat in Winning the Best Managed Companies Award

Company efforts balance strategic growth and sustainability A successful record of meeting increasing market dynamics Ongoing commitment to fulfilling ...

May 19, 2022 | News

‘Don’t be left short-changed post approval – plan in change orders early for accelerated pathways’

A post approval change order is often necessary, but innovators should plan and prepare for this pre-approval. Planning alongside outsourcing par...

May 19, 2022 | News

Bora Pharmaceuticals acquires Eden Biologics CDMO Assets

Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the establishment of ...

May 11, 2022 | News

Biomerics Announces Image Guided Intervention (IGI) Division

The goal of image-guided intervention systems is to increase the clinician's spatial navigation abilities while reducing the mental burden associated with ...

May 03, 2022 | News

Stay Connected